MENU
Showcases Stock ranks Forex

Cara Therapeutics (CARA)
11.5  0.23 (2.04%) 08-08 16:00
Open: 11.03 Pre. Close: 11.27
High: 11.65 Low: 10.9239
Volume: 622,760 Market Cap: 616M
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 11.657 - 11.691 11.691 - 11.73
Low: 10.819 - 10.86 10.86 - 10.905
Close: 11.426 - 11.489 11.489 - 11.561
Stock Technical Analysis
Overall:     
Target: Six months: 13.61
One year: 15.89
Support: Support1: 9.47
Support2: 8.13
Resistance: Resistance1: 11.65
Resistance2: 13.61
Pivot: 9.58
Moving Averages: MA(5): 10.24
MA(20): 9.52
MA(100): 9.87
MA(250): 11.88
MACD: MACD(12,26): 0.34
Signal(12,26,9): 0.12
%K %D: %K(14,3): 98.16
%D(3): 81.41
RSI: RSI(14): 70.15
52-Week: High: 18.93
Low: 7.4
Change(%): -8.3
Average Vol(K): 3-Month: 484
10-Days: 555
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.

[ CARA ] has closed above the upper band by 4.4%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 48.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
Stock chart
Stock News
Mon, 08 Aug 2022
CARA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com

Mon, 08 Aug 2022
Cara Therapeutics Reports Second Quarter 2022 Financial Results - GlobeNewswire

Mon, 18 Jul 2022
Strs Ohio Cuts Position in Cara Therapeutics, Inc. (NASDAQ:CARA) - Defense World

Tue, 10 May 2022
Cara Therapeutics stock soars after Q1 earnings beat, optimism over Korsuva U.S. launch - Seeking Alpha

Mon, 04 Apr 2022
Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA™ (difelikefalin) Injection Selected for Presentation at National Kidney Foundation Spring Clinical Meetings 2022 - GlobeNewswire

Mon, 28 Mar 2022
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Patients with Moderate-To-Severe Pruritus - GlobeNewswire

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 53.59
Shares Float (M) 44.97
% Held by Insiders 16.24
% Held by Institutions 61.49
Shares Short (K) 7030
Shares Short Prior Month (K) 6280
Stock Financials
EPS -1.800
Book Value (p.s.) 3.810
Profit Margin
Operating Margin -360.98
Return on Assets (ttm) -24.6
Return on Equity (ttm) -42.8
Qtrly Rev. Growth 147.5
Gross Profit (p.s.) -1.113
Sales Per Share 0.483
EBITDA (p.s.) -1.739
Qtrly Earnings Growth
Operating Cash Flow (M) -61.89
Levered Free Cash Flow (M) -26.80
Stock Valuation
PE Ratio -6.39
PEG Ratio -0.06
Price to Book value 3.02
Price to Sales 23.81
Price to Cash Flow -9.96
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android